SCHEMBL26888989

SCHEMBL26888989

CC(C)(CCOC(C)(C)C[C@@]12CC[C@@H](O1)[C@@H](NC(=O)C(F)(F)F)[C@@H](O)[C@H]2O)NC(=O)/C=C/C(=O)C1CCC1

nearest known ligand 0.34

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
▸ ASGR1 P07306 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25875122 0.76 ASGR1 (0.36) ASGR1
SCHEMBL18722973 0.68 ASGR1 (0.62) ASGR1
SCHEMBL26889027 0.68 ASGR1 (0.43) ASGR1
SCHEMBL26889049 0.67 ASGR1 (0.44) ASGR1
SCHEMBL25875036 0.67 ASGR1 (0.44) ASGR1
SCHEMBL26889339 0.65 ASGR1 (0.52) ASGR1
SCHEMBL25874957 0.61 ASGR1 (0.35) ASGR1
SCHEMBL18723059 0.59 ASGR1 (0.63) ASGR1
SCHEMBL18722934 0.57 ASGR1 (0.59) ASGR1
SCHEMBL27376270 0.55 ALDH1A1 (0.39) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2023-11-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11819551-B2 ASGPR-binding compounds for the degradation of extracellular proteins ASGR1, ENGASE, FCGR2A ASGR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback